HYPERTENSION AND THE GUT MICROBIOME: USING GUT MICROBES TO REDUCE BLOOD PRESSURE
Professor Francine Marques
Professor of Genetics and Genomics
Monash University, Victoria, Australia
RESEARCHER PROFILE (Filmed in Clayton, Victoria | December 2024)
Professor Francine Marques is an National Health and Medical Research Council Emerging Leader, Viertel Charitable Foundation, and National Heart Foundation Fellow.
She leads the Hypertension Research Laboratory at Monash University and has published more than 120 peer-reviewed papers in journals such as Nature Reviews Cardiology, Nature Medicine, Nature Cardiovascular Research, and Circulation.
As a researcher Professor Marques has secured over $10 million in competitive funding as a principal investigator. She has won 31 awards, including the 2019 American Heart Association Hypertension Council Goldblatt Award, the 2020 High Blood Pressure Research Council of Australia and 2021 International Society of Hypertension Mid-Career Awards, the 2021 Australian Academy of Science Gottschalk Medal, and the 2024 Australian Society of Medical Research Peter Doherty Leading Light Award, and was a finalist for 12 awards, including the Eureka Prize Emerging Leader in Science.
Her research team aims to build exceptional scientists that help improve cardiovascular health, using translational approaches to lower blood pressure via the gut microbiome. Professor Marques is also passionate about equity, diversity and inclusion (EDI) and helping communities change the current culture of research.
She has led research identifying intrinsic equity issues in the cardiovascular research community in Australia (https://pubmed.ncbi.nlm.nih.gov/32839116/), followed by research to find solutions for these issues (https://pubmed.ncbi.nlm.nih.gov/35577952/), resulting in the 2021 Women’s Agenda Emerging Leader in STEM award.
Outside work, Francine enjoys baking, travelling, spending time with family, friends and her dogs, and reading books.
https://orcid.org/0000-0003-4920-9991
-
Understanding the experience of pain for novel brain-based treatments
Associate Professor Tasha Stanton leads the Persistent Pain Research Group at SAHMRI. She is also co-Director of IIMPACT in Health at the University of South Australia, Adelaide. She is a clinical pain neuroscientist, with original training as a physiotherapist, and her research focusses on pain – why do we have it and why doesn’t it go away?
-
Nanoparticles & microparticles to combat antimicrobial resistance
Dr Anjana Jayasree is an emerging research leader in biomaterials, tissue engineering and nanotechnology, recognised internationally for her innovative work on antimicrobial nanoparticles and regenerative therapies. A Postdoctoral Research Fellow at The University of Queensland, she operates at the intersection of materials science, drug delivery and cellular biology, developing advanced metallic-based nanotechnologies to improve both human and animal health outcomes. Her expertise spans nanoparticle synthesis, cell–material interactions, and the design of sophisticated in vitro models to investigate soft-tissue integration, osseointegration, angiogenesis and biofilm formation.
-
Novel forms of brain stimulation & psychedelic assisted psychotherapy
Professor Paul Fitzgerald is the Head of the School of Medicine and Psychology at the Australian National University. He is an academic psychiatrist with a MBBS degree, Masters of Psychological Medicine and research PhD. He has conducted an extensive range of experimental studies and clinical trials, focused on the development of novel treatment options for patients with mental health conditions such as depression, schizophrenia, obsessive compulsive disorder, PTSD, autism and Alzheimer’s disease.
